An observational study in Asthma in Children, sponsored by Guangzhou Institute of Respiratory Disease. Enrolling by invitation at 1 site in China. Open to participants aged 4 Years to 16 Years. Per ClinicalTrials.gov, last updated 2025-02-28.
Sponsored by Guangzhou Institute of Respiratory Disease · Observational
How we know · 3 judgments
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies in Asthma by Guangzhou Institute of Respiratory Disease — 1 open to participants now, 1 under way, none of them phase 3. Asthma · Guangzhou Institute of Respiratory Disease.
Among the 13 studies in Asthma by Guangzhou Institute of Respiratory Disease, this one is one of 2 that started in 2022, is one of 7 observational ones, and was the 13th registered.
4,850 studies on the registry are indexed under Asthma; 604 are open to participants now.
Browse Asthma studies →1 of the 13 studies in Asthma by Guangzhou Institute of Respiratory Disease is open now, in 1 country.
By country, each count listing its studies:
Of the 416 Asthma studies recruiting now, 141 (34%) set no upper age limit and 204 (49%) stop at 75 or younger; 146 take children under 18; 105 take healthy volunteers.
This study: 4 Years to 16 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
First in 2007; this study’s year is marked. 2 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 213 is above the median of 159 across 1,254 observational studies indexed under Asthma.
Median enrollment 41 across the 6 interventional studies, 213 across the 7 observational. Of the 6 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Guangzhou Institute of Respiratory Disease is the lead sponsor of 99 studies on the registry; 18 are open to participants now.
None of the studies under way reaches primary completion within a year.
Among the 13 studies in Asthma by Guangzhou Institute of Respiratory Disease, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Observe the changes of type II inflammation markers, lung function, and symptom scores in asthmatic patients aged 6 to 14 during the use of dupilumab to analyze its efficacy.
The attending physician evaluated these patients as having type 2 inflammatory asthma based on factors such as FeNO (fractional exhaled nitric oxide) levels ≥ 20, sputum eosinophils (EOS) percentage ≥ 2%, and/or blood EOS count ≥ 300/μl.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Enrolled patients were required to have been on regular ICS-LABA therapy for at least 3-6 months without adequate control. The attending physician evaluated these patients as having type 2 inflammatory asthma based on factors such as FeNO (fractional exhaled nitric oxide) levels ≥ 20, sputum eosinophils (EOS) percentage ≥ 2%, and/or blood EOS count ≥ 300/μl. All children were prescribed with dupilumab during the study period.
Exclusion Criteria:
Patients with conditions other than asthma receiving treatment with dupilumab, individuals currently using other biologics or undergoing sublingual or subcutaneous immunotherapy, active parasitic infections, and children with immunodeficiency were excluded.
Drug: Dupilumab
initial injection of 600 mg, followed by maintenance injections of 300 mg every four weeks
FEV1
forced expiratory volume in one second
Time frame: From enrollment to the end of treatment through study completion, an average of 1 year
FVC
forced vital capacity
Time frame: From enrollment to the end of treatment through study completion, an average of 1 year
FEV1/FVC
ratio of forced expiratory volume in onesecond to forced vital capacity
Time frame: From enrollment to the end of treatment through study completion, an average of 1 year
PEF
peak expiratory flow
Time frame: From enrollment to the end of treatment through study completion, an average of 1 year
FeNO
fraction of exhaled nitric oxide
Time frame: From enrollment to the end of treatment through study completion, an average of 1 year
blood EOS
blood eosinophil count
Time frame: From enrollment to the end of treatment through study completion, an average of 1 year
percentage of sputum eosinophils
Time frame: From enrollment to the end of treatment through study completion, an average of 1 year
TIgE
serum total immunoglobulin E
Time frame: From enrollment to the end of treatment through study completion, an average of 1 year
Started Jan 2022 (actual). Primary completion is estimated for Dec 2025, 47 months after the start.
Of 366 non-industry observational studies under Asthma, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 97. This study's planned 47 months is above that.
Counting every sponsor, half of 456 studies reached it within 36 months; a quarter within 18 and three quarters within 82.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Guangzhou Institute of Respiratory Disease